Lipid Nanoparticle Delivery in COVID-19 mRNA Vaccines: Immune Mechanisms, Manufacturing Processes, and Future Perspectives
Main Article Content
Keywords
mRNA vaccine, lipid nanoparticle, COVID-19, immune response, vaccine manufacturing
Abstract
The COVID-19 mRNA vaccine is one of the most successful examples of nucleic acid vaccine technology. Rather than directly injecting the viral protein itself, this technology introduces an RNA sequence that encodes the COVID-19 virus’s spike protein into human cells. This causes the cells to temporarily produce the antigen, thereby training the immune system to recognize the virus. Since mRNA itself is easily degraded and cannot enter cells on its own, lipid nanoparticles serve as a reliable delivery system for mRNA vaccines. These lipid nanoparticles help to maintain the stability of the mRNA within the body and facilitating its uptake by cells. This article examines the use of lipid nanoparticles for delivery in COVID-19 mRNA vaccines, summarizing their basic composition, the antigen expression process following cellular uptake, the mechanisms of immune activation, large-scale production processes, and their characteristics when compared to conventional inactivated vaccines. Finally, this article discusses the potential for future improvements to this technology in terms of stability, ease of transport, rapid adaptation to viral variants, and broader vaccine development.
References
- [1] Sanders, B., Koldijk, M., & Schuitemaker, H. (2014). Inactivated viral vaccines. Vaccine Analysis: Strategies, Principles, and Control, 45–80.
- [2] Jin, L., Zhou, Y., Zhang, S., & Chen, S. J. (2025). mRNA vaccine sequence and structure design and optimization: Advances and challenges. Journal of Biological Chemistry, 301(1), 108015.
- [3] Heinz, F. X., & Stiasny, K. (2021). Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. npj Vaccines, 6, 104.
- [4] Zhai, J., Cote, T., & Chen, Y. (2024). Challenges and advances of the stability of mRNA delivery therapeutics. Nucleic Acid Insights, 1(2), 101–113.
- [5] Xu, S., Hu, Z., Song, F., Xu, Y., & Han, X. (2025). Lipid nanoparticles: Composition, formulation, and application. Molecular Therapy Methods & Clinical Development, 33(2), 101463.
- [6] Pei, D. (2025). Endosomal escape of lipid nanoparticles: A perspective on the literature data. ACS Nano, 19(47), 40293–40303.
- [7] Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021). mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nature Reviews Drug Discovery, 20, 817–838.
- [8] Quan, Y., Yang, H., Li, W., & Li, L. (2025). mRNA vaccines: immunogenicity and quality characteristics. Journal of Nanobiotechnology, 24, 6.
- [9] Pambudi, N. A., Sarifudin, A., Gandidi, I. M., & Romadhon, R. (2021). Vaccine cold chain management and cold storage technology to address the challenges of vaccination programs. Energy Reports, 8, 955–972.
- [10] Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022). COVID-19 mRNA vaccines: platforms and current developments. Molecular Therapy, 30(5), 1850–1868.
Article Sidebar
This work is licensed under a Creative Commons Attribution 4.0 International License.